Decreases in the serum VLDL-TG/Non-VLDL-TG ratio from early stages of chronic hepatitis C: Alterations in TG-Rich Lipoprotein Levels

Motoi Nishimura, Haruna Yamamoto, Toshihiko Yoshida, Masanori Seimiya, Yuji Sawabe, Kazuyuki Matsushita, Hiroshi Umemura, Kazuyuki Sogawa, Hirotaka Takizawa, Osamu Yokosuka, Fumio Nomura

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Background: The liver secretes very-low-density lipoproteins (VLDLs) and plays a key role in lipid metabolism. Plasma total triglyceride (TG) level variations have been studied in patients with hepatitis C virus (HCV)-related chronic hepatitis (CH-C). However, the results of these studies are variable. A homogenous assay protocol was recently proposed to directly measure the TG content in VLDL (VLDL-TG) and VLDL remnants. Methodology/Principal Findings: Using the assay protocol, we determined serum VLDL-TG levels in 69 fasting patients with biopsy-proven HCV-related chronic liver disease and 50 healthy subjects. Patients were classified into stages F0-F4 using the 5-point Desmet scale. Serum total TG levels in patients with non-cirrhotic (F1-F3) CH-C did not demonstrate significant differences compared with healthy subjects, but serum VLDL-TG levels did demonstrate significant differences. Mean serum VLDL-TG levels tended to decrease with disease progression from F1 to F4 (cirrhosis). Compared with healthy subjects, serum non-VLDL-TG levels significantly increased in patients with stages F2 and F3 CH-C; however, we observed no significant difference in patients with liver cirrhosis. Furthermore, the serum VLDL-TG/non-VLDL-TG ratio, when taken, demonstrated a significant decrease in patients with CH-C from the mildest stage F1 onward. Conclusions/Significance: The decrease in serum VLDL-TG levels was attenuated by increase in non-VLDL-TG levels in patients with non-cirrhotic CH-C, resulting in comparable total TG levels. Results of previous studies though variable, were confirmed to have a logical basis. The decrease in the serum VLDL-TG/non-VLDL-TG ratio as early as stage F1 demonstrated TG metabolic alterations in early stages of CH-C for the first time. The involvement of TG metabolism in CH-C pathogenesis has been established in experimental animals, while conventional TG measurements are generally considered as poor indicators of CH-C progression in clinical practice. The serum VLDL-TG/non-VLDL-TG ratio, which focuses on TG metabolic alterations, may be an early indicator of CH-C.

Original languageEnglish
Article numbere17309
JournalPLoS One
Volume6
Issue number2
DOIs
Publication statusPublished - 2011
Externally publishedYes

Fingerprint

chronic hepatitis C
very low density lipoprotein
Chronic Hepatitis C
low density lipoprotein
lipoproteins
Lipoproteins
Triglycerides
triacylglycerols
Serum
VLDL Lipoproteins
Liver
Healthy Volunteers
Viruses
Hepacivirus
Assays
low density lipoprotein triglyceride
very low density lipoprotein triglyceride
Biopsy
Metabolism
Hepatitis C virus

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Nishimura, M., Yamamoto, H., Yoshida, T., Seimiya, M., Sawabe, Y., Matsushita, K., ... Nomura, F. (2011). Decreases in the serum VLDL-TG/Non-VLDL-TG ratio from early stages of chronic hepatitis C: Alterations in TG-Rich Lipoprotein Levels. PLoS One, 6(2), [e17309]. https://doi.org/10.1371/journal.pone.0017309

Decreases in the serum VLDL-TG/Non-VLDL-TG ratio from early stages of chronic hepatitis C : Alterations in TG-Rich Lipoprotein Levels. / Nishimura, Motoi; Yamamoto, Haruna; Yoshida, Toshihiko; Seimiya, Masanori; Sawabe, Yuji; Matsushita, Kazuyuki; Umemura, Hiroshi; Sogawa, Kazuyuki; Takizawa, Hirotaka; Yokosuka, Osamu; Nomura, Fumio.

In: PLoS One, Vol. 6, No. 2, e17309, 2011.

Research output: Contribution to journalArticle

Nishimura, M, Yamamoto, H, Yoshida, T, Seimiya, M, Sawabe, Y, Matsushita, K, Umemura, H, Sogawa, K, Takizawa, H, Yokosuka, O & Nomura, F 2011, 'Decreases in the serum VLDL-TG/Non-VLDL-TG ratio from early stages of chronic hepatitis C: Alterations in TG-Rich Lipoprotein Levels', PLoS One, vol. 6, no. 2, e17309. https://doi.org/10.1371/journal.pone.0017309
Nishimura, Motoi ; Yamamoto, Haruna ; Yoshida, Toshihiko ; Seimiya, Masanori ; Sawabe, Yuji ; Matsushita, Kazuyuki ; Umemura, Hiroshi ; Sogawa, Kazuyuki ; Takizawa, Hirotaka ; Yokosuka, Osamu ; Nomura, Fumio. / Decreases in the serum VLDL-TG/Non-VLDL-TG ratio from early stages of chronic hepatitis C : Alterations in TG-Rich Lipoprotein Levels. In: PLoS One. 2011 ; Vol. 6, No. 2.
@article{a0d0ebd06ffa4f3dbc8a9410eac098e6,
title = "Decreases in the serum VLDL-TG/Non-VLDL-TG ratio from early stages of chronic hepatitis C: Alterations in TG-Rich Lipoprotein Levels",
abstract = "Background: The liver secretes very-low-density lipoproteins (VLDLs) and plays a key role in lipid metabolism. Plasma total triglyceride (TG) level variations have been studied in patients with hepatitis C virus (HCV)-related chronic hepatitis (CH-C). However, the results of these studies are variable. A homogenous assay protocol was recently proposed to directly measure the TG content in VLDL (VLDL-TG) and VLDL remnants. Methodology/Principal Findings: Using the assay protocol, we determined serum VLDL-TG levels in 69 fasting patients with biopsy-proven HCV-related chronic liver disease and 50 healthy subjects. Patients were classified into stages F0-F4 using the 5-point Desmet scale. Serum total TG levels in patients with non-cirrhotic (F1-F3) CH-C did not demonstrate significant differences compared with healthy subjects, but serum VLDL-TG levels did demonstrate significant differences. Mean serum VLDL-TG levels tended to decrease with disease progression from F1 to F4 (cirrhosis). Compared with healthy subjects, serum non-VLDL-TG levels significantly increased in patients with stages F2 and F3 CH-C; however, we observed no significant difference in patients with liver cirrhosis. Furthermore, the serum VLDL-TG/non-VLDL-TG ratio, when taken, demonstrated a significant decrease in patients with CH-C from the mildest stage F1 onward. Conclusions/Significance: The decrease in serum VLDL-TG levels was attenuated by increase in non-VLDL-TG levels in patients with non-cirrhotic CH-C, resulting in comparable total TG levels. Results of previous studies though variable, were confirmed to have a logical basis. The decrease in the serum VLDL-TG/non-VLDL-TG ratio as early as stage F1 demonstrated TG metabolic alterations in early stages of CH-C for the first time. The involvement of TG metabolism in CH-C pathogenesis has been established in experimental animals, while conventional TG measurements are generally considered as poor indicators of CH-C progression in clinical practice. The serum VLDL-TG/non-VLDL-TG ratio, which focuses on TG metabolic alterations, may be an early indicator of CH-C.",
author = "Motoi Nishimura and Haruna Yamamoto and Toshihiko Yoshida and Masanori Seimiya and Yuji Sawabe and Kazuyuki Matsushita and Hiroshi Umemura and Kazuyuki Sogawa and Hirotaka Takizawa and Osamu Yokosuka and Fumio Nomura",
year = "2011",
doi = "10.1371/journal.pone.0017309",
language = "English",
volume = "6",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "2",

}

TY - JOUR

T1 - Decreases in the serum VLDL-TG/Non-VLDL-TG ratio from early stages of chronic hepatitis C

T2 - Alterations in TG-Rich Lipoprotein Levels

AU - Nishimura, Motoi

AU - Yamamoto, Haruna

AU - Yoshida, Toshihiko

AU - Seimiya, Masanori

AU - Sawabe, Yuji

AU - Matsushita, Kazuyuki

AU - Umemura, Hiroshi

AU - Sogawa, Kazuyuki

AU - Takizawa, Hirotaka

AU - Yokosuka, Osamu

AU - Nomura, Fumio

PY - 2011

Y1 - 2011

N2 - Background: The liver secretes very-low-density lipoproteins (VLDLs) and plays a key role in lipid metabolism. Plasma total triglyceride (TG) level variations have been studied in patients with hepatitis C virus (HCV)-related chronic hepatitis (CH-C). However, the results of these studies are variable. A homogenous assay protocol was recently proposed to directly measure the TG content in VLDL (VLDL-TG) and VLDL remnants. Methodology/Principal Findings: Using the assay protocol, we determined serum VLDL-TG levels in 69 fasting patients with biopsy-proven HCV-related chronic liver disease and 50 healthy subjects. Patients were classified into stages F0-F4 using the 5-point Desmet scale. Serum total TG levels in patients with non-cirrhotic (F1-F3) CH-C did not demonstrate significant differences compared with healthy subjects, but serum VLDL-TG levels did demonstrate significant differences. Mean serum VLDL-TG levels tended to decrease with disease progression from F1 to F4 (cirrhosis). Compared with healthy subjects, serum non-VLDL-TG levels significantly increased in patients with stages F2 and F3 CH-C; however, we observed no significant difference in patients with liver cirrhosis. Furthermore, the serum VLDL-TG/non-VLDL-TG ratio, when taken, demonstrated a significant decrease in patients with CH-C from the mildest stage F1 onward. Conclusions/Significance: The decrease in serum VLDL-TG levels was attenuated by increase in non-VLDL-TG levels in patients with non-cirrhotic CH-C, resulting in comparable total TG levels. Results of previous studies though variable, were confirmed to have a logical basis. The decrease in the serum VLDL-TG/non-VLDL-TG ratio as early as stage F1 demonstrated TG metabolic alterations in early stages of CH-C for the first time. The involvement of TG metabolism in CH-C pathogenesis has been established in experimental animals, while conventional TG measurements are generally considered as poor indicators of CH-C progression in clinical practice. The serum VLDL-TG/non-VLDL-TG ratio, which focuses on TG metabolic alterations, may be an early indicator of CH-C.

AB - Background: The liver secretes very-low-density lipoproteins (VLDLs) and plays a key role in lipid metabolism. Plasma total triglyceride (TG) level variations have been studied in patients with hepatitis C virus (HCV)-related chronic hepatitis (CH-C). However, the results of these studies are variable. A homogenous assay protocol was recently proposed to directly measure the TG content in VLDL (VLDL-TG) and VLDL remnants. Methodology/Principal Findings: Using the assay protocol, we determined serum VLDL-TG levels in 69 fasting patients with biopsy-proven HCV-related chronic liver disease and 50 healthy subjects. Patients were classified into stages F0-F4 using the 5-point Desmet scale. Serum total TG levels in patients with non-cirrhotic (F1-F3) CH-C did not demonstrate significant differences compared with healthy subjects, but serum VLDL-TG levels did demonstrate significant differences. Mean serum VLDL-TG levels tended to decrease with disease progression from F1 to F4 (cirrhosis). Compared with healthy subjects, serum non-VLDL-TG levels significantly increased in patients with stages F2 and F3 CH-C; however, we observed no significant difference in patients with liver cirrhosis. Furthermore, the serum VLDL-TG/non-VLDL-TG ratio, when taken, demonstrated a significant decrease in patients with CH-C from the mildest stage F1 onward. Conclusions/Significance: The decrease in serum VLDL-TG levels was attenuated by increase in non-VLDL-TG levels in patients with non-cirrhotic CH-C, resulting in comparable total TG levels. Results of previous studies though variable, were confirmed to have a logical basis. The decrease in the serum VLDL-TG/non-VLDL-TG ratio as early as stage F1 demonstrated TG metabolic alterations in early stages of CH-C for the first time. The involvement of TG metabolism in CH-C pathogenesis has been established in experimental animals, while conventional TG measurements are generally considered as poor indicators of CH-C progression in clinical practice. The serum VLDL-TG/non-VLDL-TG ratio, which focuses on TG metabolic alterations, may be an early indicator of CH-C.

UR - http://www.scopus.com/inward/record.url?scp=79952169333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=79952169333&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0017309

DO - 10.1371/journal.pone.0017309

M3 - Article

C2 - 21364889

AN - SCOPUS:79952169333

VL - 6

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 2

M1 - e17309

ER -